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Background & Aims: Factors that affect outcomes of patients with non-alcoholic 
steatohepatitis (NASH) related cirrhosis are unclear. We studied associations of type 2 
diabetes, levels of hemoglobin A1c (HbA1c), and use antidiabetic medications with survival 
and liver-related events in patients with NASH and compensated cirrhosis. 
Methods: We collected data from 299 patients with biopsy-proven NASH with 
Child-Pugh A cirrhosis from tertiary hospitals in Spain, Australia, Hong Kong, and Cuba, 
from April 1995 through December 2016. We obtained information on presence of type 2 
diabetes, level of HbA1c, and use of antidiabetic medications. Cox proportional and 
competing risk models were used to estimate and compare rates of transplant-free survival, 
hepatic decompensation, and hepatocellular carcinoma (HCC). 
Results: Two-hundred and twelve patients had type 2 diabetes at baseline and 8/87 patients 
developed diabetes during a median follow-up time of 5.1 y (range, 0.5–10.0 y). A lower 
proportion of patients with diabetes survived the entire follow-up period (38%) than of 
patients with no diabetes (81%) (adjusted hazard ratio [aHR], 4.23; 95% CI, 1.93–9.29). 
Higher proportions of patients with diabetes also had hepatic decompensation (51% vs 26% 
of patients with no diabetes; aHR, 2.03; 95% CI 1.005–4.11) and HCC (25% vs 7% of 
patients with no diabetes; aHR, 5.42; 95% CI 1.74–16.80). Averaged annual HbA1c levels 
over time were not associated with outcomes. Metformin use over time was associated with a 
significant reduction in risk of death or liver transplantation (aHR, 0.41; 95% CI, 0.26–0.45), 
hepatic decompensation (aHR, 0.80; 95% CI, 0.74–0.97), and HCC (aHR, 0.78; 95% CI, 
0.69–0.96). Metformin significantly reduced risk of hepatic decompensation and HCC only in 
subjects with HbA1c levels above 7.0% (aHR, 0.97; 95% CI, 0.95–0.99 and aHR, 0.67; 95% 
CI, 0.43–0.94, respectively). 
Conclusions: In an international cohort of patients with biopsy-proven NASH and Child-
Pugh A cirrhosis, type 2 diabetes increased risk of death and liver-related outcomes, including 
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HCC. Patients who took metformin had higher rates of survival and lower rates of 
decompensation and HCC. 
Key words: chemoprevention, glucose intolerance, ascites, encephalopathy, fatty 
liver  
Non-alcoholic fatty liver disease (NAFLD) is a leading cause of cirrhosis and an increasingly 
common indication for liver transplantation.(1, 2) Moreover, NAFLD is responsible for an 
increasing number of hepatocellular carcinoma (HCC) cases with reports from the United 
States demonstrating a rate increase of around 9% per annum.(3, 4) Consequently, mortality 
rates within the US from non-alcoholic steatohepatitis (NASH) related cirrhosis and HCC 
have also increased significantly over the last decade.(5) Overall, the long-term clinical 
course of NAFLD is markedly influenced by the severity of fibrosis, whereby patients with 
cirrhosis are at greatest risk of developing liver-related complications (6, 7). Defining risk 
factors for adverse outcomes in NASH cirrhosis patients is important to identify factors that 
may be modifiable in order to improve outcomes. In addition, it may aid prioritization for 
clinical trials and for more intense monitoring.   
NAFLD and T2DM frequently coexist; retrospective cohort studies including patients 
with biopsy-proven NAFLD have reported that T2DM increases the risk of all-cause, cardiac 
and liver related mortality.(8-10) Population-level data (not limited to NAFLD patients) 
indicates that T2DM is associated with an increased risk of HCC.(11) Moreover, T2DM has 
been associated with increased risk of liver-related complications (hepatic decompensation 
and HCC) in patients with chronic liver disease (CLD).(12, 13) However, the majority of 
these studies were conducted in subjects with diverse etiologies of CLD, or with limited 
numbers of NASH cirrhosis patients who are at most risk of liver complications. Thus, 
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whether T2DM increases the risk of hepatic outcomes, irrespective of severity of liver 
disease, remains to be elucidated.   
Among patients with T2DM, the use of anti-diabetic medications (ADMs) and 
glycemic control may modify the risk of HCC.(14-16) Recent meta-analyses of diabetic 
patients have documented that metformin treatment is associated with decreased HCC risk, 
whereas insulin and sulphonylureas use is linked with a higher risk.(17, 18)  Whether this 
protective effect is observed in NASH cirrhosis patients is unknown. Similar findings have 
been observed for overall cancers and ADMs, although it is uncertain whether this effect is 
independent of glycemic control.(16, 19) Thus, T2DM may represent an important modifiable 
risk factor through the use of ADM’s or via improved glycemic control.  To explore this 
further, we aimed to determine the influence of T2DM, hyperglycemia and ADMs on 
outcomes of HCC, liver decompensation and death in an international multicentre cohort of 
NASH patients with compensated cirrhosis. 
 
MATERIAL AND METHODS 
 
Study design and participants 
The design and subject exclusion criteria for this international multicenter cohort study has 
been described previously with additional information in the Supplementary material.(6)  
Overall, 458 with biopsy-proven advanced NASH (septal/bridging fibrosis or 
compensated cirrhosis) were followed from April 1995 until December 2016 in six tertiary 
hospitals from 4 countries (Spain [n=184], Australia [n=116], Hong Kong [n=82] and Cuba 
[n=76]). Analysis was restricted to those with compensated cirrhosis at baseline (n=299). The 
prospective registries and study protocol were approved by the Institutional Review Board of 




Liver biopsies were scored locally by expert liver pathologists using the NASH-CRN scoring 
system.(20) Biopsies prior to the implementation of the NASH-CRN scoring system in 2006 
were re-evaluated.(6) Hepatic steatosis ≥5% with ballooning and/or lobular inflammation was 
required to confirm NASH diagnosis (see supplementary methods for more details). 
Clinical, biochemical and demographic data 
Data for demographics (age, sex, race/ethnicity), comorbidities, anthropometry, fasting serum 
determinations (glucose, HbA1c, insulin, lipids, liver function tests, INR, creatinine, alpha-
fetoprotein), alcohol consumption and cigarette smoking within 30 days of liver biopsy were 
obtained.  
Evaluation of glucose-related parameters and anti-diabetic medications 
T2DM was defined at baseline as fasting glucose ≥126 mg/dL or HbA1c ≥6.5% or use of 
ADMs.(21) Data on new diagnoses of T2DM, type of ADM (metformin, sulphonylurea, 
insulin and others) as well as date of commencement and cessation of ADM’s was recorded 
during follow-up from medical and pharmacy records.  ADMs users were defined as patients 
who took drug for at least the first 6 months of follow-up. Patients were categorized into four 
groups: (1) Metformin users; (2) Sulfonylurea users; (3) Insulin users (4) non-ADMs users. 
Patients on combination medications were considered users of both drugs. (22) Use of other 
ADM agents (Glucagon-Like Peptide-1 Receptor agonists, sodium glucose transport protein 2 
inhibitors, thiazolidinediones) was infrequent (<5% of cohort) and thus not analysed. 
Glycemic control during follow-up was determined according to the average annual HbA1c 
which was calculated for each patient by summing annual HbA1c values and dividing by the 
number of years of follow-up plus one, to account for the baseline value. 
Follow-up and events assessment 
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Follow-up began on the date of biopsy, and ended on the date of the last visit, death, or 
transplant.  A detailed medical history and physical examination along with laboratory tests 
were performed at each visit.  Patients underwent 6 monthly ultrasound screening for HCC. 
Gastroscopies were performed at the discretion of the local investigator following 
recommended guidelines.(23) The primary outcome was all-cause death or liver 
transplantation. Secondary outcomes were the development of liver decompensation and 
HCC. Patients lost to follow-up were censored at the last date known to be alive. 
Major clinical outcomes definitions 
(1) Liver decompensation was defined by the: occurrence of ascites (identified clinically or by
ultrasound), upper gastrointestinal bleeding secondary to portal hypertension (confirmed by 
endoscopy in the presence of gastroesophageal varices or hypertensive gastropathy), hepatic 
encephalopathy (established by clinical parameters, neuropsychological tests, or 
electroencephalogram). 
(2) HCC diagnosed by dynamic CT scan, MRI or biopsy.
Only the index event in each category was analyzed. Outcomes occurring after liver 
transplantation were not considered. 
Statistical analysis 
The baseline characteristics were summarized in percentages (categorical variables) or mean 
± SD or median and range (continuous variables). Categorical variables were compared using 
χ
2 test. Continuous variables were compared using the t test for normally distributed variables 
and the nonparametric Wilcoxon rank-sum test for measures not normally distributed.  
The primary analysis was to explore the influence of diabetes, ADM’s and HbA1c 
values on death/transplant and hepatic outcomes (see supplementary methods).    
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The cumulative probability of death or transplant based on T2DM status, HbA1c cut-offs and 
ADMs was analyzed by the Cox proportional method. Cumulative incidences of secondary 
outcomes (first event of hepatic decompensation and HCC), were calculated in the presence 
of competing risks events.(24)  Annualized incidence rates and 95% confidence intervals for 
outcomes among diabetic and non-diabetic patients were reported.  Missing values were 
imputed by applying the multiple imputations method (see supplementary methods).  All 
confidence intervals, significance tests, and resulting P values were two-sided, with an alpha 
level of 0.05. Statistical analyses were performed using STATA software, release 15.  
 
RESULTS 
Of 512 patients within the cohort, 299 patients had NASH-related cirrhosis and fulfilled the 
inclusion criteria (Figure 1).  The overall follow-up was a median of 5.1 years (range 0.5-10 
years). Compared with non-diabetic patients (n=87), diabetics (n=212) at baseline were older, 
had more hypertension, gastroesophageal varices and worse renal function (Table 1).  Of the 
87 patients without diabetes at baseline, eight (9%) developed type 2 diabetes during follow-
up, a mean of 5.5 (± 1.3) years following liver biopsy.   The majority of diabetic patients 
(79%) were on ADMs including metformin (n=111), sulfonylureas (n=61) and insulin (n=87).  
Less frequent ADMs were: pioglitazone/rosiglitazone (3%), DPP-4 (4%) or SGLT2i (3%). 
Insulin users displayed higher HbA1c and creatinine values as compared with metformin and 
sulphonylureas users ( upplementary Table 1). 
 
Type 2 diabetes mellitus: Impact on transplant-free survival and hepatic outcomes.  
Overall survival and transplant 
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A total of 70 patients died (n=33) or underwent liver transplantation (n=37).  Most deaths 
were liver-related (29 of 33, 87%).  Causes of death and occurrence of major clinical events 
among diabetic and non-diabetic patients are summarized in supplementary Table 2. 
   Ten-year survival without transplantation was significantly lower in diabetic patients 
(38%, 95% CI:31-45) compared with non-diabetics (81%, 95% CI:75-88). Annualized 
mortality or transplant rates were 4.9 and 3.0 /100 person-years, in diabetic and non-diabetic 
patients respectively, (Cox-adjusted P<0.01, Figure 2A, Table 2). Other predictors of overall 
mortality/transplant rates on univariate analysis are reported in Supplementary Table 3.  
Multivariable Cox-adjusted analysis revealed T2DM increased the risk of all-cause mortality 
or transplant 4.59 (95% CI:2.23-9.43) times as compared with no T2DM. This remained 
significant when analysing T2DM as a time-dependent variable (adj. HR 4.23, 95% CI:1.93-
9.29, p<0.001). 
Hepatocellular carcinoma 
Thirty-nine patients developed HCC; Nine underwent transplantation and seven died 
due to HCC. At 10 years, patients with diabetes were more likely to develop HCC (25%, 95% 
CI:18-30) than those without diabetes (7%, 95% CI:3-13), P<0.01. The annualized rates (/100 
person-years) for HCC were 3.1 and 1.2 in diabetic and non-diabetic patients, respectively 
(Figure 2B, Table 2). On multivariate analysis, a 4.2-fold (95% CI:1.2-14.2) increased risk of 
HCC was observed among diabetics versus non-diabetics. T2DM remained a significant 
predictor of HCC when analysed as a time-dependent variable (adj.sHR 5.42, 95% CI:1.74-
16.80, p=0.003). 
Hepatic decompensation 
Ascites (60/83) and variceal bleeding (18/83) were the most common initial events of 
decompensation. The 10-year adjusted cumulative incidence of hepatic decompensation was 
higher in patients with T2DM (51%, 95% CI:44-59) than those without T2DM (26%, 95% 
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CI:17-33), P<0.01, corresponding to annual rates of 6.6 and 4.2, respectively (F gure 2C, 
Table 2). T2DM increased the risk of hepatic decompensation 2.46 times (95% CI:1.35-4.46) 
compared with no T2DM.   When analysed as a time-dependent co-variate, T2DM remained 
significantly predictive of decompensation (adj.sHR 2.03, 95% CI:1.005-4.11, p=0.048). 
 Anti-diabetic medications: Impact on transplant-free survival and hepatic outcomes  
An overview of antidiabetic medications duration, cessation and new users during follow up 
is described in Supplementary material.   Use of metformin at baseline, compared to non-use, 
was associated with a higher cumulative probability of transplant-free survival (78%, 95% 
CI:71-85 vs. 44%, 95% CI:37-52 P<0.01), and lower cumulative incidence of hepatic 
decompensation (45%, 95% CI:37-52 vs. 60%, 95% CI:55-68, P=0.047), Figure 3A-B.  HCC 
rates were not significantly different in baseline metformin users (10%, 95% CI:6-17) vs. non-
users (14%, 95% CI:8-22), Figure 3C. At multivariable analysis (Table 3), metformin (as a 
time dependent variable) was independently associated with reduced risk of all-cause 
mortality (HR: 0.41, 95% CI:0.26-0.45, P<0.001), hepatic decompensation (sHR: 0.80, 95% 
CI:0.74-0.97, P=0.005), and HCC (sHR 0.78, 95% CI:0.69-0.96), P=0.047). Adjustment for 
statin use or HOMA-IR did not change the association between metformin and outcomes 
(data not shown).   
The benefits of metformin use on transplant-free survival were observed in patients 
with an HbA1c ≤7% (n=178) and >7% (n=121) (adj.HR: 0.93, 95% CI:0.89-0.98 and adj.HR 
0.87, 95% CI:0.84-0.90 respectively), however the association with hepatic decompensation 
and HCC was only seen in patients with HbA1c of >7% (adj.sHR 0.97, 95% CI:0.95-0.99 and 
adj.sHR 0.67, 95% CI:0.45-0.94 respectively), outlined in Supplemental Table 4.  
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HbA1c and HOMA-IR levels: Influence on transplant-free survival and hepatic 
outcomes.  
Overall, average annual HbA1c values were not associated with transplant free survival 
[HR:1.09 (95% CI:0.92-1.29), P=0.30], hepatic decompensation [sHR:1.07 (95% CI:0.93-
1.24), P=0.32] or development of HCC [sHR:1.11 (0.89-1.37), P=0.34]. Whilst the risk of 
overall mortality or transplant tended to increase per quartile of average annual HbA1c 
values, this did not reach statistical significance (Supplementary Table 5, Supplementary 
Figure 1A-C).  Among diabetic patients, HOMA-IR at baseline was not associated with 
outcomes (Supplementary Table 6).  Among diabetics not taking insulin at baseline, 
HOMA-IR was associated with an increased risk of mortality/transplant on univariate 
analysis, however this did not remain significant following adjustment for potential 
confounders (HR 0.99, 95% CI 0.94-1.04, p=0.9). 
 
DISCUSSION 
In this multicenter, international cohort study of patients with biopsy-proven NASH 
cirrhosis, diabetic patients were at significantly higher risk of adverse outcomes compared to 
non-diabetics; one quarter of NASH-cirrhosis patients with T2DM died or underwent liver 
transplantation during a median of five years follow-up, with these patients having more than 
four-fold increased risk compared to those without diabetes. Similarly, T2DM was associated 
with a higher risk of hepatic decompensation and HCC even following adjustment for major 
confounders including use of glucose-lowering medications. Significantly, metformin use had 
a protective association for overall mortality and transplant, hepatic decompensation and 
HCC.  
Although T2DM has been associated with detrimental liver outcomes among patients 
with the full-histological spectrum of NAFLD, its impact on survival and liver-related events 
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in cirrhotic patients has been unclear.(10, 25) Population-based studies have demonstrated 
T2DM to be associated with higher standardized mortality ratios for liver related death, 
although the absolute risk of death in patients with T2DM in these cohorts remained low.(10, 
26, 27) Our data clearly demonstrates that in the presence of compensated cirrhosis, T2DM 
identifies an at-risk group at high probability of developing liver related morbidity and 
mortality over the medium term, thereby indicating a need for heightened surveillance and 
prioritization for effective therapy.  There was an unexpected low rate of death from 
cardiovascular disease in T2DM patients with NASH cirrhosis, which may reflect the 
reduction in blood pressure, body weight and cholesterol which occurs with progressive 
fibrosis, or due to competing risks from liver disease limiting opportunity for cardiovascular 
disease to manifest. 
Growing evidence has linked T2DM and HCC, independently of recognized 
confounding factors such as obesity, age, sex, patterns of alcohol consumption, cirrhosis and 
chronic viral hepatitis.(4, 28, 29) Nonetheless, a single-center cohort study and multicentre 
case-control study both failed to demonstrate a link between HCC and T2D in NASH 
cirrhosis patients.(30, 31) In contrast, our data demonstrated T2DM to be robustly associated 
with HCC risk, irrespective of well-known confounders, likely due to the larger sample size 
and follow-up.  
The use of metformin was associated with a 59%, 20% and 22% reduction in risk of 
all-cause mortality or transplant, hepatic decompensation and HCC respectively. Notably, no 
patient developed lactic acidosis or serious complications from metformin use, in line with 
other reports.(32) However, the safety and efficacy of metformin in decompensated cirrhosis 
is not clear and caution should be applied using it. Clinical trials have been conflicting 
regarding the impact of metformin on liver histology in non-cirrhotic NASH patients, and a 
lack of adequately powered randomized controlled trials has prevented recommendation for 
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its use in patients with NASH.(33, 34) Interestingly, the continued use of metformin after 
cirrhosis diagnosis was associated with improved survival in a single center study, 
particularly among NASH cirrhosis patients, although it is unclear whether this was due to 
reduced rates of liver decompensation, HCC or extra-hepatic disease.(32) The protective 
effect of metformin in a NASH population was also recently noted in a retrospective study 
based on 191 biopsy proven NASH (86% cirrhosis) patients where metformin users had a 
lower risk of all-cause death and liver transplant and HCC compared to non-users.(35) Given 
the significant reduction in mortality associated with metformin use in our cohort, our data 
provides rationale to examine the impact of metformin in a prospective randomized clinical 
trial on NASH cirrhosis outcomes. We lacked data on newer ADM’s such as 
thiozoladinediones and glucagon-like peptide-1 receptor agonists. These agents came into 
routine clinical use relatively late in the follow-up period and it is likely the study would have 
been under-powered to detect a significant association with outcomes. 
In the context of HCC, results from several clinical studies have indicated that type 2 
diabetic patients treated with metformin might have a lower risk of any cancer (36) and this 
protective effect appears to be particularly important for gastrointestinal- malignancies 
including HCC.(17, 37) We did not find a protective association between metformin and 
HCC, though there was a non-significant trend, raising the possibility that our study could be 
underpowered to detect an effect.  
Our study has a number of strengths, being a multicenter, international and multiethnic 
study consisting of a large cohort of patients with histologically-confirmed cirrhosis followed 
for a long period with very few patients lost to follow-up. To our knowledge, this is the 
biggest cohort of biopsy proven NASH patients with compensated cirrhosis in which the 
influence of diabetes, its medications and baseline glucose levels on survival and liver-related 
outcomes has been investigated. Our results also need to be interpreted with caution because 
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of study limitations. Firstly, it is a retrospective analysis with risk of bias, although this has 
been minimized by standardized baseline data collection at each unit, minimal loss to follow-
up and the examination of hard outcomes such as mortality. Second, although HbA1c is an 
accurate diagnostic test for T2DM in Childs A cirrhosis (area under the curve 0.85), we 
cannot exclude that anemia or elevated red cell turnover may have impacted on HbA1c levels 
and its relationship on outcomes over time.(38) In addition, it is possible that HbA1c 
progressively underestimated glucose control during long-term follow-up in patients who 
developed worsening cirrhosis, such that any association with worsening glycemic control 
and outcomes was missed.  
  In conclusion, in this cohort study, T2DM was associated with an increased risk of 
death, hepatic decompensation and HCC. These associations suggest the need for close 
surveillance for these high-risk patients in order to reduce death and complications. 
Metformin may lower the risk of death and liver-related events and warrants further well-
designed studies to clarify the beneficial or harmful effects of ADMs on outcomes among 
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Figure 1.  Flow diagram of patients in the study  
Figure 2. Adjusted cumulative probability of outcomes according to presence of Type 2 
diabetes.  
(A) Transplant-free survival
(B) First occurrence of hepatic decompensation
(C) First occurrence of hepatocellular carcinoma
* Slopes and P values represent adjusted predictions by center, calendar year of patients’
recruitment, age, sex, race/ethnicity, BMI, smoking status, alcohol consumption, CTP score, 
esophageal varices, HbA1c levels and glucose-lowering medications at baseline. 
Fig. 3. Impact of metformin use on major outcomes. Analyses based on all-users versus non-
users.  
(A) Cox model-adjusted *transplant-free survival rates.
(B) Competing risk-adjusted *hepatic decompensation rates.
(C) Competing risk-adjusted *hepatocellular carcinoma rates.
* Slopes represent adjusted predictions by center, calendar year of patients’ recruitment, age,
sex, race/ethnicity, BMI, smoking status, alcohol consumption, CTP score, esophageal 
varices, HbA1c levels and glucose-lowering medications at baseline. 
Hazard ratio’s are reported using metformin as a time-dependent co-variate. 
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Table 1. Baseline characteristics.  
Variable 
No type 2 
diabetes 
n=87 




Age (y) 52.5 ± 13.2 58.9 ± 10.3 <0.01 
Male, n (%) 38 (44) 101 (48) 0.53 
Race/ethnicity 0.02 
  Hispanic white 57 (66) 123 (58) 
  Non-Hispanic white 20 (23) 47 (22) 
  Asian 7 (8) 41 (19) 
  Black 3 (3) 1 (1) 
Current smoker 18 (21) 34 (16) 0.61 
BMI (kg/m2)    33.1 ± 8.8 31.8 ± 6.1 0.67 
Waist (cm) 105.5 ± 15.3 106.1 ± 16.1 0.95 
Length of follow-up 5.6 (3.1-8.8) 5.0 (2.5-8.3) 0.10 
MELD score 8.0 ± 2.5 8.4 ± 3.1 0.35 
Child-Pugh score, n (%) 
   Class A6 21 (24) 56 (26) 0.68 
Gastroesophageal varices, n (%) 10 (11) 75 (35) <0.01 
History of hypertension, n (%) 43 (49) 141 (67) <0.01 
Anti-diabetic medications, n (%) 0 (0) 168 (79) - 
   Non-users, n (%)  0 (0) 44 (21) - 
   Metformin users, n (%) 0 (0) 111 (52) - 
   Sulfonylureas users, n (%) 0 (0) 62 (29) - 
   Insulin users, n (%) 0 (0) 87 (41) - 
   DDP-4 inhibitors, n (%) 0 (0) 8 (4) - 
   SGLT2 inhibitors, n (%) 0 (0) 6 (3) - 
   Glitazones, n (%) 0 (0) 7 (3) - 
ALT (U/L) 79 ± 55 56 ± 37 0.35 
AST (U/L) 83 ± 59 52 ± 31 0.10 
AST/ALT ratio 1.18 ± 0.57 1.07 ± 0.39 0.47 
γ-Glutamyl transferase (U/L) 116 ± 98 155 ± 135 0.02 
Fasting glucose (mg/dl) 92.8 ± 12.1 168.1 ± 62.8 <0.01 
HbA1c (%) 5.39 ± 0.51 7.82 ± 2.07 <0.01 
Fasting insulin (mIU/L) 16.2 ± 8.9 24.8 ± 13.2 <0.01 
HOMA-IR 3.78 ± 2.3 11.26 ± 9.01 <0.01 
Total cholesterol (mg/dl) 175.4 ± 47.3 176.4 ± 54.8 0.95 
HDL cholesterol (mg/dl) 45.9 ± 13.2 43.1 ± 10.6 0.27 
LDL cholesterol (mg/dl) 99.3 ± 39.9 104.9 ± 47.9 0.59 
Triglycerides (mg/dl)  149.4 ± 69.8 163.9 ± 79.5 0.14 
Statin therapy, n (%) 14 (16) 79 (37) <0.01 
Total bilirubin (mg/dl) 1.07 ± 0.84 0.91 ± 0.67 0.07 
Albumin (g/dl) 4.14 ± 0.41 4.16 ± 0.40 0.53 
INR 1.13 ± 0.33 1.09 ± 0.16 0.80 
Platelets (x 109/L)  172 ± 65 165 ± 64 0.31 
α-fetoprotein (ng/ml) 3.6 ± 1.8 3.7 ± 1.8 0.92 
Creatinine (mg/dl) 0.80 ± 0.19 0.93 ± 0.46 <0.01 
eGFR, mL/min/1.73m2 93.9 ± 17.7 81.7 ± 24.7 <0.01 
eGFR <60 mL/min/1.73m2 3 (3) 42 (20) <0.01 
History of vascular disease, n (%) 9 (7) 19 (9) 0.55 
History of malignancy, n (%) 1 (1) 7 (3) 0.30 
Aspirin therapy, n (%) 4 (5) 10 (6) 0.96 
Biopsy length (mm) 18.9 ± 4.9 18.8 ± 5.01 0.83 
Portal tracts (n) 9.36 ± 2.5 9.58 ± 2.4 0.18 
NAS 3.82 ± 1.83 4.11 ± 1.87 0.21 
NAS ≥ 4, n (%) * 46 (53) 134 (63) 0.10 
Individual component of NAS     
  Steatosis 1.68 ± 0.81 1.63 ± 0.87 0.69 
  Lobular inflammation 1.17 ± 0.36 1.37 ± 0.81 0.07 
  Ballooning 0.97 ± 0.76 1.11 ± 0.74 0.17 
Country, n (%) 0.09 
   Spain§ 36 (41) 82 (39) 
   Australia 20 (23) 48 (23) 
   Hong-Kong 7 (8) 40 (18) 
   Cuba 24 (28) 42 (20) 
Abbreviations: BMI, body mass index; MELD, Model for End-Stage Liver Disease; ALT, 
alanine aminotransferase; AST, aspartate aminotransferase; HbA1c, glycated hemoglobin; 
HOMA-IR, Homeostatic Model Assessment of Insulin Resistance; INR, international 
normalized ratio; eGFR, estimated glomerular filtration rate; NAS, NAFLD activity score.  
Quantitative data expressed as mean ± SD.    
Length of follow variable expressed as median and range 
For all laboratory measures and for continuous demographics: T test or Wilcoxon rank-sum 
test. 
Proportions: percentage, Chi-Square test.  
The eGFR was computed by EPI-CKD formula. 
* NAS indicates NAFLD activity score. It was defined as the unweighted sum of the scores
for steatosis (0-3), lobular inflammation (0-3), and ballooning (0-2); thus, ranging from 0 to 
8.
Table 2. Annualized incidence rates of clinical outcomes in NASH cirrhosis patients according 






No. Rates 95% CI No. Rates 95% CI 
All deaths or transplantations 15 3.00 1.81-4.98 55 4.89 3.76-6.37 
Hepatic decompensation 19 4.19 2.67-6.57 64 6.63 5.19-8.48 
Development of HCC 6 1.21 0.54-2.70 33 3.11 2.21-4.37 
Total major vascular events* 1 0.28 0.02-1.42 5 0.45 0.18-1.07 
Total non-hepatic malignancies 6 1.25 0.56-2.77 7 0.63 0.30-1.33 
* Major vascular events included cardiovascular, cerebrovascular, and arterial peripheral 
diseases.  
Recurrence of clinical events and skin cancers were not included. 
Table 3. Risk of mortality/transplant, hepatic decompensation and HCC based on the use of anti-




Hazard* or subhazard† 
ratio (95% CI) 
 Hazard* or subhazard† 






 Mortality or transplant 
Metformin  0.32 (0.24-0.41) <0.001 0.41 (0.26-0.45) <0.001 
Insulin          1.31 (0.74-2.29)   0.34          0.85 (0.41-1.78)    0.66 
Sulphonylurea               0.76 (0.41-1.41)   0.39 1.26 (0.65-2.46)   0.48 
 Hepatic decompensation 
Metformin  0.78 (0.68-0.90) 0.001         0.80 (0.74-0.97)  0.005 
Insulin           1.72 (1.01-2.92) 0.04 2.30 (1.19-4.44) 0.012 
Sulphonylurea 0.62 (0.36-1.05) 0.08 0.83 (0.49-1.43) 0.519 
 Hepatocellular carcinoma 
Metformin  0.27 (0.64-1.68) 0.16 0.78 (0.69-0.96) 0.047 
Insulin 1.92 (0.91-4.05) 0.08 1.84 (0.65-5.19) 0.244 
Sulphonylurea          0.60 (0.26-1.42) 0.25 0.96 (0.36-2.61) 0.947 
* Cox proportional regression hazard models. 
† Competing risk regression models. 
‡ Adjustments by center, calendar year of patients’ recruitment, age, sex, race/ethnicity, BMI, 
smoking status, alcohol consumption, CTP score, esophageal varices, annual average HbA1c 
levels. ADM’s were analysed as time-dependent co-variates. 











What you need to know:  
Background: Little is known about the effects of type 2 diabetes and diabetic medications on 
long-term outcomes of patients with non-alcoholic steatohepatitis (NASH)-related cirrhosis. 
 
Findings Type 2 diabetes significantly increased risk of death and liver transplantation, 
hepatic decompensation, and hepatocellular carcinoma in patients with NASH-related 
cirrhosis. Use of metformin was associated with a reduced risk of death or liver transplant, 
hepatic decompensation, and hepatocellular carcinoma. 
 
Implications for patient care: Patients with NASH and diabetes are at increased risk of 
adverse outcomes, compared to patients with NASH without diabetes. Metformin use might 
reduce the risk of liver-related morbidity and mortality in this group. 
 
 
